Meningococcal conjugate vaccines policy update: Booster dose recommendations

Michael T. Brady, Henry H. Bernstein, Carrie L. Byington, Kathryn M. Edwards, Margaret C. Fisher, Mary P. Glode, Mary Anne Jackson, Harry L. Keyserling, David W. Kimberlin, Yvonne A. Maldonado, Walter A. Orenstein, Gordon E. Schutze, Rodney E. Willoughby, Robert Bortolussi, Marc A. Fischer, Bruce Gellin, Richard L. Gorman, Lucia Lee, R. Douglas Pratt, Jane SewardJeffrey R. Starke, Jack Swanson, Tina Q. Tan

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics approved updated recommendations for the use of quadravalent (serogroups A, C, W-135, and Y) meningococcal conjugate vaccines (Menactra [Sanofi Pasteur, Swiftwater, PA] and Menveo [Novartis, Basel, Switzerland]) in adolescents and in people at persistent high risk of meningococcal disease. The recommendations supplement previous Advisory Committee on Immunization Practices and American Academy of Pediatrics recommendations for meningococcal vaccinations. Data were reviewed pertaining to immunogenicity in high-risk groups, bactericidal antibody persistence after immunization, current epidemiology of meningococcal disease, meningococcal conjugate vaccine effectiveness, and cost-effectiveness of different strategies for vaccination of adolescents. This review prompted the following recommendations: (1) adolescents should be routinely immunized at 11 through 12 years of age and given a booster dose at 16 years of age; (2) adolescents who received their first dose at age 13 through 15 years should receive a booster at age 16 through 18 years or up to 5 years after their first dose; (3) adolescents who receive their first dose of meningococcal conjugate vaccine at or after 16 years of age do not need a booster dose; (4) a 2-dose primary series should be administered 2 months apart for those who are at increased risk of invasive meningococcal disease because of persistent complement component (eg, C5-C9, properdin, factor H, or factor D) deficiency (9 months through 54 years of age) or functional or anatomic asplenia (2-54 years of age) and for adolescents with HIV infection; and (5) a booster dose should be given 3 years after the primary series if the primary 2-dose series was given from 2 through 6 years of age and every 5 years for persons whose 2-dose primary series or booster dosewasgiven at 7 years of age or olderwhoare at risk of invasive meningococcal disease because of persistent component (eg, C5-C9, properdin, factor H, or factor D) deficiency or functional or anatomic asplenia.

Original languageEnglish (US)
Pages (from-to)1213-1218
Number of pages6
Issue number6
StatePublished - Dec 2011


  • Adolescents
  • Immunization
  • Meningitis
  • Meningococcal vaccine
  • Vaccination

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Meningococcal conjugate vaccines policy update: Booster dose recommendations'. Together they form a unique fingerprint.

Cite this